Proposals For Drug Pricing Reforms In Germany Come Under Heavy Political And Industry Pressure
This article was originally published in The Pink Sheet Daily
State elections in North Rhine-Westphalia could lead to a softening of German drug-pricing reforms.
You may also be interested in...
With the German drug price freeze set to continue, the pharmaceutical industry wants to see at least an inflation-linked rise in prices and the abandonment of HTA for older products.
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.
Over the past few months, cuts to pharmaceutical prices have been announced in Ireland, Germany and Greece. France, Spain and Italy are preparing to make similar moves